• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IMU

IMUGENE LIMITED - Corporate Spotlight

0.00% ! 1.5¢
Market Cap $112.0M  !

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing... Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs. More

No Corporate Spotlight currently available.

Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
1.5¢
Change
0.000(0.00%)
Mkt cap ! $112.0M
Open High Low Value Volume
1.5¢ 1.6¢ 1.4¢ $125.4K 8.369M

Buyers (Bids)

No. Vol. Price($)
76 17029463 1.4¢
 

Sellers (Offers)

Price($) Vol. No.
1.5¢ 1061875 3
View Market Depth
Last trade - 16.10pm 13/06/2025 (20 minute delay) ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.